Search results for " plasminogen activator"

showing 10 items of 77 documents

Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia

1991

In pregnancy a decrease in fibrinolytic activity, which is due to an increase in plasminogen activator inhibitor activity and plasminogen activator inhibitor type 1 and type 2, has been described. Because the placenta is a source of both type 1 and type 2 plasminogen activator inhibitor, we have studied them and other fibrinolytic parameters in a group of normotensive pregnant women with intrauterine fetal growth retardation and in two groups of women with preeclampsia, with or without intrauterine growth retardation. A significant increase in plasminogen activator inhibitor type 1 antigen and plasminogen activator inhibitor activity was observed in preeclampsia, with or without intrauterin…

Adultmedicine.medical_specialtymedicine.medical_treatmentBlood PressurePreeclampsiaPre-EclampsiaAntigenPregnancyReference ValuesInternal medicinePlacentaFibrinolysismedicineFetal growthHumansPregnancyFetal Growth Retardationbusiness.industryFibrinolysisObstetrics and Gynecologymedicine.diseaseUrokinase-Type Plasminogen ActivatorPathophysiologyPlasminogen Inactivatorsmedicine.anatomical_structureEndocrinologyTissue Plasminogen ActivatorImmunologyFemalebusinessPlasminogen activatorAmerican Journal of Obstetrics and Gynecology
researchProduct

Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.

2006

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in > patients with bone metastasis (BMTS) and the possible correlation with the symptomatic > response induced by this drug in these patients were evaluated. Patients and Methods: > Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the > plasma of 30 patients with painful bone metastases from breast or prostate cancer > undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects > (HS) of…

Aged 80 and overMaleBone Density Conservation AgentsDiphosphonatesZoledronic > acidImidazolesProstatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedProteinaseZoledronic AcidCathepsin BMatrix > metalloproteinase-9Matrix Metalloproteinase 9Matrix metalloproteinase-2Bone metastasiBisphosphonates; Bone metastasis; Cathepsin B; Matrix metalloproteinase-2; Matrix > metalloproteinase-9; Proteinases; Urokinase-type plasminogen activator; Zoledronic > acidHumansMatrix Metalloproteinase 2BisphosphonateFemaleUrokinase-type plasminogen activatorAged
researchProduct

Principles and requirements for stroke recovery science

2020

The disappointing results in bench-to-bedside translation of neuroprotective strategies caused a certain shift in stroke research towards enhancing the endogenous recovery potential of the brain. One reason for this focus on recovery is the much wider time window for therapeutic interventions which is open for at least several months. Since recently two large clinical studies using d-amphetamine or fluoxetine, respectively, to enhance post-stroke neurological outcome failed again it is a good time for a critical reflection on principles and requirements for stroke recovery science. In principal, stroke recovery science deals with all events from the molecular up to the functional and behav…

Agingmedicine.medical_specialtyCombination therapymedicine.medical_treatmenttranslationNeuroprotectioncombination therapyrecovery03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationchronic strokeHumansMedicineReview ArticlesChronic strokeStroke030304 developmental biologyNeurotransmitter Agents0303 health sciencesbusiness.industryRegeneration (biology)BrainRecovery of Functionmedicine.diseaseStrokeMatrix Metalloproteinase 9NeurologyTissue Plasminogen ActivatorregenerationIntercellular Signaling Peptides and ProteinsNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke recovery030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

Inhibition of Histone Deacetylase Activity in Human Endometrial Stromal Cells Promotes Extracellular Matrix Remodelling and Limits Embryo Invasion

2011

Invasion of the trophoblast into the maternal decidua is regulated by both the trophoectoderm and the endometrial stroma, and entails the action of tissue remodeling enzymes. Trophoblast invasion requires the action of metalloproteinases (MMPs) to degrade extracellular matrix (ECM) proteins and in turn, decidual cells express tissue inhibitors of MMPs (TIMPs). The balance between these promoting and restraining factors is a key event for the successful outcome of pregnancy. Gene expression is post-transcriptionally regulated by histone deacetylases (HDACs) that unpacks condensed chromatin activating gene expression. In this study we analyze the effect of histone acetylation on the expressio…

Anatomy and PhysiologyGene ExpressionHydroxamic AcidsEndometriumEndocrinologyPregnancyMolecular Cell BiologyCells Culturedreproductive and urinary physiologyRegulation of gene expressionMultidisciplinarybiologyQRObstetrics and GynecologyExtracellular MatrixChromatinCell biologyHistonemedicine.anatomical_structureMatrix Metalloproteinase 9embryonic structuresMatrix Metalloproteinase 2MedicineFemaleHistone deacetylase activityResearch Articlemedicine.drugAdultStromal cellScienceDown-RegulationGene Expression Regulation EnzymologicYoung AdultmedicineHumansEmbryo ImplantationBiologyTissue Inhibitor of Metalloproteinase-3Tissue Inhibitor of Metalloproteinase-1Reproductive SystemTrophoblastUrokinase-Type Plasminogen ActivatorMolecular biologyHistone Deacetylase InhibitorsTrichostatin AAcetylationbiology.proteinStromal CellsDevelopmental Biology
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Enhanced platelet thromboxane synthesis and reduced macrophage-dependent fibrinolytic activity related to oxidative stress in oral contraceptive-trea…

1996

Abstract In previous studies conducted in rats and in women, we have shown that oral contraceptive (OC) administration induced a platelet hyperaggregation simultaneously with an increased platelet lipid biosynthesis which might be related to lipid peroxidation. In the present study, we specifically studied the arachidonic acid and the fibrinolytic pathways in relation to the fatty acid composition in female rats treated for 6 weeks with OC (ethinyl estradiol plus lynestrenol). We found that platelets of treated animals were not only hyper-responsive to thrombin and ADP, but also to sodium arachidonate. In addition, the results of the thrombin-induced release of labeled arachidonic acid pre-…

Blood Plateletsmedicine.medical_specialtyErythrocytesPlatelet AggregationThromboxaneRadioimmunoassayLipid peroxidationRats Sprague-Dawleychemistry.chemical_compoundThromboxane A2Internal medicineLipid biosynthesisThromboembolismmedicineAnimalsArachidonic AcidFibrinolysisThromboxanesUrokinase-Type Plasminogen ActivatorRecombinant ProteinsRatsThromboxane B2Disease Models AnimalOxidative StressEndocrinology12-Hydroxyheptadecatrienoic acidchemistryMacrophages Peritoneal12-Hydroxyeicosatetraenoic acidArachidonic acidFemaleLipid PeroxidationCardiology and Cardiovascular MedicineContraceptives OralAtherosclerosis
researchProduct

2015

The recombinant form of tissue plasminogen activator (rt-PA) is the only curative treatment for ischemic stroke. Recently, t-PA has been linked to the metabolism of brain-derived neurotrophic factor (BDNF), a major neurotrophin involved in post-stroke neuroplasticity. Thus, the objective of our study was to investigate the impact of rt-PA treatment on post-stroke circulating BDNF levels in humans and in animals. Serum BDNF levels and t-PA/plasmin activity were measured at hospital admission and at up to 90 days in stroke patients receiving (n = 24) or not (n = 14) rt-PA perfusion. We investigated the relationships between serum BDNF with concurrent t-PA/plasmin activity, neurological outcom…

Brain-derived neurotrophic factor0303 health sciencesmedicine.medical_specialtyPathologyMultidisciplinaryPlasminbusiness.industrymedicine.diseaseTissue plasminogen activator3. Good healthBrain ischemia03 medical and health sciences0302 clinical medicineEndocrinologyBlood pressurenervous systemInternal medicinemedicineEndothelial dysfunctionbusinessStroke030217 neurology & neurosurgeryFibrinolytic agent030304 developmental biologymedicine.drugPLOS ONE
researchProduct

THE ASSOCIATION BETWEEN PROGRESSION OF POST-SURGICAL CALF VEIN THROMBOSIS AND 4G/5G POLYMORPHSM IN THE PROMOTER OF THE PLASMINOGEN ACTIVATOR INHIBITOR

2006

CALF VEIN THROMBOSIS 4G/5G POLYMORPHSM PLASMINOGEN ACTIVATOR INHIBITOR
researchProduct

Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

2004

Cathepsin D is a lysosomal acid proteinase which is involved in the malignant progression of breast cancer and other gynecological tumors. Clinical investigations have shown that in breast cancer patients cathepsin D overexpression was significantly correlated with a shorter free-time disease and overall survival, whereas in patients with ovarian or endometrial cancer this phenomenon was associated with tumor aggressiveness and a degree of chemoresistance to various antitumor drugs such as anthracyclines, cis-platinum and vinca alkaloids. Therefore, a lot of research has been undertaken to evaluate the role and the prognostic value of cathepsin D also in other solid neoplasms. However, conf…

Cancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsSkin NeoplasmsCathepsin DAntineoplastic AgentsBiologyDigestive System NeoplasmsCathepsin DMetastasisCentral Nervous System NeoplasmsBreast cancerSurgical oncologyNeoplasmsmedicineBiomarkers TumorNeoplasmHumansClinical significanceThyroid NeoplasmsMelanomaEndometrial cancerGeneral Medicinecathepsin D lysosomal proteinases matrix-metalloproteinases metastasis neoplasm plasminogen activator prognosis tumor progressionmedicine.diseaseNeoplasm ProteinsOncologyTumor progressionHead and Neck NeoplasmsDrug DesignCancer researchDisease ProgressionLysosomesUrogenital NeoplasmsClinicalexperimental metastasis
researchProduct

Transforming growth factor-β1, β2, and β3, urokinase and parathyroid hormone-related peptide expression in 8701-BC breast cancer cells and clones

1993

8701-BC is a recently characterized cell line isolated from a primary ductal infiltrating carcinoma of the breast (d.i.c.), showing some pleomorphism in cell microanatomy at an ultrastructural level. We have obtained different sublines of 8701-BC cells by cloning in soft agar at different concentrations (0.3% and 0.6%), and we have characterized the cloned lines by some morphological and growth parameters. 8701-BC cells and clones have been submitted to analysis by reverse transcriptase-linked polymerase chain reaction to detect mRNAs of various cytokines (transforming growth factor-beta s, tumour necrosis factors, interleukin 1s, interleukin 6, parathyroid hormone-related peptide, gamma in…

Cancer Researchmedicine.medical_specialtyMolecular Sequence DataParathyroid hormoneBreast NeoplasmsPolymerase Chain ReactionTransforming Growth Factor betaInternal medicineGene expressionBiomarkers TumorTumor Cells CulturedmedicineHumansRNA MessengerMolecular BiologyBase SequencebiologyParathyroid hormone-related proteinInterleukin-6Tumor Necrosis Factor-alphaCarcinoma Ductal BreastParathyroid Hormone-Related ProteinProteinsInterleukinCell BiologyTransforming growth factor betaUrokinase-Type Plasminogen ActivatorMolecular biologyIn vitroClone CellsPhenotypeEndocrinologyCell culturebiology.proteinInterleukin-1Developmental BiologyTransforming growth factorDifferentiation
researchProduct